CTOs on the Move

Forest Grove Care Centre

www.fgcc.ab.ca

 
Forest Grove Care Centre Ltd. is a Calgary, AB-based company in the Business Services sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.fgcc.ab.ca
  • 4726 8 Ave SE
    Calgary, AB CAN T2A 0A8
  • Phone: 403.272.9831

Executives

Name Title Contact Details

Similar Companies

LAKE MICHIGAN CONTRACTORS INC

LAKE MICHIGAN CONTRACTORS INC is a Holland, MI-based company in the Business Services sector.

Morton Photonics

Morton Photonics Incorporated is a West Friendship, MD-based company in the Business Services sector.

Icahn Automotive Group

Icahn Automotive Group LLC was formed by its parent, Icahn Enterprises L.P., to invest in and operate businesses involved in aftermarket parts distribution and service.

Fircroft

Fircroft is a global workforce solutions provider to the technical engineering industries. Since 1970 Fircroft has been serving the biggest names in Oil & Gas, Petrochemical & Chemical, ICT, Mining & Minerals, Infrastructure & Construction, Power, Nuclear & Renewables and Automotive. Today, over 12,000 contractors trust Fircroft to take care of their careers.

Skye Bioscience Inc.

Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.